Amphion Innovations Share Discussion Threads

[65jack] 27/3/2015 13:52

This will keep running till IPO next week. Also weekend press will be onto this

[65jack] 27/3/2015 13:42

See you at 18p chesty boy

[chesty1] 27/3/2015 13:41

not pumped on this bb but it is on others.....

[65jack] 27/3/2015 13:26

The IPO will value AMP between 12-18p. Bit of a no brainer at these levels.

[cottoner] 27/3/2015 12:55

If anyone's been 'pumping' it's been the Daily Mail ! :-)

[timberwolf3] 27/3/2015 12:52

Cheesty - 8 posts today, hardly pumping.

[h2owater] 27/3/2015 12:41

Shares outstanding 150.77m
Free float 57.99m

[chesty1] 27/3/2015 12:39

Anyone for a dump.....Its a cumin.

[chesty1] 27/3/2015 12:32

WOW great p&d going on here.......Watch this fall from this level of 7p....

Crazy......Anyone buying in now wants shooting.

[h2owater] 27/3/2015 12:12

MARKET REPORT: Excited investors can't wait to splash cash on Motif BioSciences which begins trading on AIM next week

By GEOFF FOSTER FOR THE DAILY MAIL
PUBLISHED: 01:03, 25 March 2015 | UPDATED: 01:09, 25 March 2015

View comments
An absolute tidal wave of mergers in biotechs over the past year or so – where smaller firms have been acquired by cash-rich major drug companies looking for a new source of growth – shows no signs of abating.

With that in mind, excited investors can’t wait to splash the cash on shares of Motif BioSciences, a New York-based drug discovery and development company, which begin trading on AIM next Tuesday.

Motif is initially raising £5m, at around 20p a share, which allows it to not only list but complete on the acquisition of Nuprim, a private company that holds exclusive worldwide development rights to iclaprim, a novel antibiotic designed to be effective against MRSA and multi-drug resistant bacteria.

Immediately post the listing, it will also undertake a fundraising of up to £16m to support the development of iclaprim.

+1
Antibiotic-resistant infections kill 50,000 people a year in the US and Europe and one of the greatest risks posed to modern medicine has been the rise and spread of microbe resistance to antibiotics, particularly for hospital-acquired infections.

Analysts are confident that iclaprim could prove to be a blockbuster treatment in this field. A Phase II clinical trial showed excellent clinical cure rates among patients treated with iclaprim and there is now a strong chance it will soon get US Food & Drug Administration approval to start a Phase 3 clinical programme suitable for NDA submission.

Analysts at Equity Development are of the opinion that once iclaprim gets the green light from the FDA, Motif’s stockmarket rating will soar and the company will be on the shopping lists of all the Big Pharma companies, if it isn’t already. The post-IPO value of the business could therefore be in the range of £45m-£60m and positive phase three results for iclaprim could double this figure.


Read more:

[h2owater] 27/3/2015 12:08

Richard Morgan, CEO of Amphion, said:

“Resistance to antibiotics is a major global public-health crisis. The most urgent need for novel antibiotics effective against multi-drug resistant bacteria is in the hospital setting where patients often succumb to serious, life-threatening infections that require immediate treatment with the best available antibiotic.

“The Acquisition of this clinical stage antibiotic is a game changer for Motif. As a result of change in the regulatory environment geared to encourage new antibiotics, we believe we have identified the right course for regulatory approval. Motif’s upcoming IPO will fund this exciting plan and we believe will generate and return value to both Motif and Amphion shareholders alike. ”

[danieljackson] 27/3/2015 08:41

Morgan to concentrate on motif bio I suppose.

[timberwolf3] 27/3/2015 07:25

KROMEK RNS

27 March 2015



Kromek Group plc

("Kromek" or the "Company")



Directorate Change





Kromek, a radiation detection technology company focusing on the medical, security and nuclear markets, announces that it has been informed by its Chairman and Director, Mr Richard Morgan, of his intention to step down from his position and the Board of Directors with immediate effect. Mr. Richard Morgan is resigning to focus on his other business interests.



Professor Brian Tanner, Deputy Chairman of Kromek, said: "Richard has been an important source of influence and has helped us since he first joined us in 2005 and more importantly as our Chairman since 2008, taking us through the IPO process and beyond. We wish him well in the future."



Professor Tanner will act as Chairman until the board elects a new Chairman and the Company will report progess on that in due course.

[timberwolf3] 26/3/2015 11:01

cottoner - I have just sent Motif an email asking for clarification, will let you know when I get reply.

[cottoner] 26/3/2015 10:41

Motif-Bio updated schedule 1 just released.

Expected Admission date changed from March 31st to April 2nd.

Strange, since the AMP RNS released on Jan 19th wrt to Motif acquisition contains

"Completion of the Acquisition is conditional inter-alia upon Motif completing an IPO before 31 March 2015."

[cottoner] 26/3/2015 10:04

Another Bio - Redx Pharma Plc floats tomorrow , Fri March 27th.

Capital to be raised on Admission: £15.0 million
Market capitalisation on Admission: £55.2 million

64,981,209 ordinary shares of 1 pence each in the capital of the Company at a price of 85 pence per share

Will be interesting to see what reaction it gets tomorrow.

[cottoner] 25/3/2015 14:54

Interview with Richard Morgan CEO Amphion Innovations on Motif Bio IPO




where .... is directorstalk

[cottoner] 25/3/2015 09:05

The value of AMP's holding in Motif won't be reflected necessarily at the IPO price but how the price of Motif performs going forwards.
Initial soundings appear positive.

[timberwolf3] 25/3/2015 08:47

Great article , I'm in this morning.

[aughton 3] 25/3/2015 08:38

what about the debt?

[moreforus] 25/3/2015 08:12

thats what Geoff of the Daily UKIP suggests

[113mike] 25/3/2015 08:07

So logic says we could be a 4 or 5 bag from here?.....

[moreforus] 25/3/2015 07:33

So Geoff Foster of the Daily Mail says

45-60 mill post ipo value with potential to double on a good result.....

there will be an ipo to raise 5 mill and then another raising for 16 mill

and AMP own 38% of Motif

38% = 17-22 mill of 45-60 mill

AMPs market cap is 5 mill

the ipo details given its coming in 6 days must have been distributed by now....